Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

2025-01-21 08:00:20 ET

Summary

• Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops.
• Eye injections are tough on patients, so this bodes well for OCS-01. OCS-05 and OCS-02 also target interesting TAMs in neuro-ophthalmology and DMD.
• OCS’s cash runway should last until late 2026, but if they don’t generate an FDA-approved product soon, it could become an issue for shareholders.
• Still, I see a few catalysts with upcoming regulatory milestones, like an NDA for OCS-01 in Q1, that could help sustain OCS stock’s valuation.
• I recommend a DCA strategy because Oculis stock might consolidate after such an impressive rally recently.

Oculis overview

Read the full article on Seeking Alpha

For further details see: